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Slater (Editors), Springer.Blood and Marrow Transplant Handbook is an excellent
handbook: concise and easy to understand. It is useful for
blood and marrow transplantation (BMT) “beginners,” and it
is convenient to consult during patient care. It has value for
the experienced clinician with reviews of BMT clinical care
and topics, such as the business of BMT and long-term care
issues, that might be less familiar to a clinician focusing on
acute BMT care. The manual is valuable for a physician
covering a BMT service as a hospitalist or for the referring
physician who will be caring long-term for a BMT patient.
The editors and authors are to be lauded for generating a
second edition, updating their previous endeavor from 2010.
Many BMT “Washington manual” formatted books have not
beneﬁtted from continued follow-up. The authors have taken
great care to provided updated information.
Some clinical practice methods can be “Oregon-centric.”
As an example, in chapter 7, the authors state that the
“standard” way to administer melphalan is 100 mg/m2 over
2 days instead of 200mg/m2 as a single dose. It can be argued
that 1 person’s standard is another person’s variance. The
infection prophylaxis chapter prefaces some recommenda-
tions with “At our center..” This is helpful for the novice,
distinguishing practices that are center-speciﬁc compared
with those that are widely used. Some recommendations,
such as how often to see a patient after BMT, no yogurt
during the period of neutropenia, and avoidance of enox-
aparin for deep vein thrombosis prophylaxis during throm-
bocytopenia, are not speciﬁed as “this is what we do in
Oregon.” The chapter on hematopoietic stem cell sources and
donor selection provides donor selection information forhttp://dx.doi.org/10.1016/j.bbmt.2015.08.041
1083-8791/ 2016 American Society for Blood and Marrow Transplantation.matched related and unrelated donors, but it could use more
detail regarding haploidentical transplantation. The latter is
a difﬁcult topic because of wide variation as to the type of
regimen, stem cell source, and type of graft-versus-host
disease prophylaxis. In the pretransplantation medical eval-
uation section, chemo-refractory disease is listed as an
exclusion criterion, which is not necessarily standard, espe-
cially for selected cases of lymphoma or acute myeloid leu-
kemia. However, all clinicians would prefer a patient in
remission. This section has valuable tables detailing risk
stratiﬁcation by disease. The infectious disease chapter
contains very nice guidelines on how to dose ganciclovir.
Hopefully, the next edition will include foscarnet dosing.
The authors did not cite references in text; instead, they
list all the references at the end of the chapter. This may be
because of publisher requirements, but it makes it cumber-
some to ﬁgure out which original article is relevant to
different chapter sections. The full names for some abbrevi-
ations need to be given in the text or the glossary. For
example, in chapter 3, page 31, SDF-1a is used, and on page
36, ATG.
These are minor points relative to the overall excellence
of the book. The psychiatric complications chapter contains
an extensive listing of antidepressants, with recommenda-
tions for use along with appropriate side-effect monitoring.
The chapters on late effects including pulmonary, cardio-
vascular, endocrine complications, women’s hormonal
issues, and secondary malignancies are especially note-
worthy. These sections are very helpful for the referring
physician managing the allogeneic BMT patient who has
returned home from the transplantation center. The ﬁrst
edition is currently for sale on Amazon in paperback andwell
as Kindle; however, you may want the second edition, which
we found at Barnes and Nobles and Springer on line. We look
forward to the next editiondhopefully within 5 years!ACKNOWLEDGMENTS
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